- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02542397
LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients
LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Pilot Study of Pain Management in Oncology Outpatients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All subjects will be assessed and prescribed a pain regimen as part of standard practice at the initial visit. Subjects will provide a buccal swab for pharmacogenomic testing and will be discharged on their initial pain regimen.
After the initial visit, subjects will be asked to rate their daily pain on a scale of 0-10. A coordinator will follow up with the subject within 7 days (Assessment #1). Subjects will be asked to report information about their pain scores, pain medication use, and caffeine intake, in addition to any bothersome symptoms. Subjects who continue to have "uncontrolled pain", are experiencing bothersome symptoms, and/or requests for a drug/dose modification will have his/her drug/dose modified using the pharmacogenomic test results. If the subject has had significant pain improvement, stable mild pain and/or is satisfied with their level of pain at the assessment (regardless of pain score), he/she will be recommended to continue the current drug/dose and return to clinic on day 30 for the final follow-up. Subjects will be told to call if their pain becomes intolerable or if they experience bothersome symptoms after Assessment #1 for further drug/dose modification if needed prior to day 30.
The coordinator will follow up with the subjects receiving a drug/dose modification after another 7 days (Assessment #2). Subjects who have now had significant pain improvement, stable mild pain, and/or are satisfied with their level pain at the assessment (regardless of pain score) will continue on the same regimen. If the subjects' pain is still "uncontrolled", they are experiencing bothersome symptoms, and/or they request a drug/dose modification, their drug/dose will be modified accordingly. Subjects will be told to call if needed, otherwise they will be seen in clinic on day 30 (Final Assessment).
If the subject experiences intolerable pain prior to any scheduled assessment, the subject will call for appropriate drug/dose modification.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of uncontrolled malignant pain (score of greater than or equal to 2 on an 11 point scale [0-10]) as diagnosed and assessed by the Investigator, using the Edmonton Symptom Assessment Scale (ESAS).
- Documentation of any stage of cancer of any tumor location (solid or hematological).
- At least 18 years of age.
- Either nociceptive or neuropathic pain.
- Able to understand and be willing to sign the study consent form.
Exclusion Criteria:
- Inpatient service at baseline visit.
- Significant dysphagia and inability to swallow oral medications as determined by the Investigator.
- Active or recent (within one year) drug and/or alcohol abuse as determined by the Investigator.
- Significant baseline cognitive impairment, as determined by the Investigator. Known (anaphylactic) hypersensitivity to any opioid.
- Severe oral mucositis that would impair proper buccal testing as determined by the Investigator.
- Receiving concurrent rehabilitation medicine care, nociception modulation (e.g., electrical stimulation), use of modalities with physiologic effects that indirectly influence nociception (e.g., light, laser therapy), or any other non-pharmacologic approaches to pain management other than exercise, rest, ice, compression, and elevation (RICE).
- Presence of major psychiatric disorders as determined by the Investigator.
- Receiving active treatment or prophylaxis for epilepsy.
- Unable or unwilling to sign the study consent form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pharmacogenomic Testing
Pharmacogenomic test results to guide drug/dose modifications
|
Pharmacogenomic test results to guide drug/dose modifications
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Pain Improvement as Measured Using the Edmonton Symptom Assessment Scale (ESAS) From Baseline Assessment (Day 0) to Final Assessment on Day 30 +/- 7
Time Frame: Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))
|
Proportion of subjects achieving significant pain improvement over a one month period (30 days +/- 7) (defined as a ≥ 2 point decrease from baseline pain score on an 11-point scale [0-10]) in oncology outpatients receiving pharmacogenomic testing.
|
Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morphine Equivalent Daily Doses (MEDD) in Milligrams
Time Frame: Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))
|
Describe the distribution of morphine equivalent daily dose (MEDD) in the evaluable population.
The MEDD was calculated and recorded at the Final Assessment for each subject by converting the subject's total daily opioid consumption at the Final Assessment to morphine equivalent doses using the following website: http://www.globalrph.com/narcoticonv.htm
(widely used across many health systems for drug/dose conversions and fully referenced).
|
Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))
|
Percentage of Subjects With an Actionable Genotype, Defined as the Presence of Any Mutation(s) That is (Are) Used to Guide a Drug/Dose Modification
Time Frame: Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))
|
An actionable genotype is defined as the presence of at least one mutation that is used to guide a drug/dose modification during Assessment 1, Assessment 2, or any unscheduled visit.
|
Enrollment to Final Assessment (30 +/- 7 days from Baseline Assessment (Day 0))
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jai Patel, PharmD, Atrium Health Levine Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LCI-NOS-PAIN-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Tumor of Ill-defined Site
-
Weill Medical College of Cornell UniversityCompletedBrain Tumors With Ill-defined MarginsUnited States
-
M.D. Anderson Cancer CenterPfizer; ISA Pharmaceuticals B.V.CompletedOropharyngeal Cancer | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and PharynxUnited States
-
Second Military Medical UniversityUnknownAdvanced Biliary Tract Malignant TumorChina
-
Henan Cancer HospitalNot yet recruitingPerioperative Period | Malignant Tumor of Bone
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityWithdrawnLocal Recurrence of Malignant Tumor of Breast
-
M.D. Anderson Cancer CenterMerck Sharp & Dohme LLC; BioMed Valley Discoveries, IncActive, not recruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms of Mesothelial... and other conditionsUnited States
-
Eye & ENT Hospital of Fudan UniversityPeking University Third Hospital; Zhongshan Ophthalmic Center, Sun Yat-sen... and other collaboratorsRecruitingMalignant Tumor of Lacrimal Drainage StructureChina
-
Hillel Yaffe Medical CenterUnknownMalignant Tumor of Women's Reproductive SystemIsrael
-
Fudan UniversityUnknownLocal Recurrence of Malignant Tumor of Soft TissueChina
-
M.D. Anderson Cancer CenterEisai Inc.WithdrawnAdvanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms... and other conditions
Clinical Trials on Pharmacogenomic Testing
-
Tabula Rasa HealthCareWithdrawnElderly | Adverse Drug Event | Pharmacogenomics | Drug Drug InteractionUnited States
-
Tabula Rasa HealthCareEnrolling by invitationPolypharmacy | PharmacogenomicsUnited States
-
Mayo ClinicCompleted
-
Wake Forest University Health SciencesCompleted
-
Columbia UniversityTerminated
-
Second Affiliated Hospital, School of Medicine,...CompletedDepressive Disorder | Pharmacogenomic Drug InteractionChina
-
J.J.SwenKarolinska Institutet; Medical University of Vienna; Uppsala University; St. Antonius... and other collaboratorsCompletedAdverse Drug ReactionAustria, Netherlands, Italy, Greece, Slovenia, Spain, United Kingdom
-
AB Biotics, SAHospital Clinic of BarcelonaCompleted
-
University of ArizonaOneOme, LLCNot yet recruitingDepression, Anxiety
-
John Papastergiou Pharmacy LtdGreen Shield CanadaCompletedDepression | Mood Disorders | Generalized Anxiety Disorder | Anxiety | Major Depressive DisorderCanada